Certified by Founder
Lodge
AvenCell
start up
United States
- Cambridge, Massachusetts
- 22/10/2024
- Series B
- $112,000,000
Based on our deep science and focused on patients in need, we develop next generation immunotherapies for hard-to-treat cancers.
- Industry Biotechnology
- Website https://avencell.com/
- LinkedIn https://www.linkedin.com/company/avencell/
Healthfab | $2,100,000 | (May 5, 2026)
Kibu, Inc | $10,500,000 | (May 5, 2026)
Fun | $72,000,000 | (May 5, 2026)
Featherless AI | $20,000,000 | (May 5, 2026)
LakeFusion | $7,500,000 | (May 5, 2026)
Enzo Health | $20,000,000 | (May 5, 2026)
Barocal | $10,000,000 | (May 5, 2026)
Zapdos Labs | $500,000 | (May 5, 2026)
Creati AI | $20,000,000 | (May 1, 2026)
Blomma | $5,000,000 | (May 1, 2026)
Dreambase | $3,700,000 | (May 1, 2026)
DISA Technologies, Inc. | $33,000,000 | (May 1, 2026)